PMID: 7017244Mar 1, 1981Paper

Antithymocyte globulin in cadaver kidney transplantation: a randomized trial based on T-cell monitoring

Kidney International
H KreisJ Crosnier

Abstract

The influence of horse antihuman thymocyte globulin (ATG) on renal allograft survival was assayed between March 1977 and August 1978. Fifty consecutive patients were randomly assigned to the treatment or the control group. Patients in both groups received azathioprine and prednisolone. ATG was added in the experimental group. The daily dosage was such as to maintain the rosette-forming cell (RFC) level at 10% of baseline values. The number of renal failure episodes (RFE's)was significantly lower in the experimental group during the period (1 month) ATG was given than it was in the control group during that same period of time. Two years after transplantation, kidney survival was 79% in the ATG group and 52% in the control group. The amount of steroids necessary to control RFE's was significantly lower in the ATG group. The dosages of ATG used in the experimental group were relatively small (average daily dose, 3.08 +/- 0.26 mg/kg of body wt), and adverse reactions were mild. Blood tolerance was excellent. T-cell monitoring thus appears to be an effective method in evaluating the daily dosage of ATG.

References

Oct 1, 1979·Transplantation·W J WechterH Ko
Dec 1, 1979·Transplantation·C F ShieldP S Russell
Apr 3, 1976·British Medical Journal·T TurszJ F Bach
Apr 1, 1973·Archives of Surgery·J G TurcotteN W Thompson
May 20, 1971·The New England Journal of Medicine·J A MannickD C Nabseth

❮ Previous
Next ❯

Citations

Jan 1, 1991·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·D J Norman, M R Leone
Nov 4, 2000·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·M M Millar, L C Grammer
Dec 10, 1981·The New England Journal of Medicine
Jul 14, 2010·Transplantation Proceedings·N A Neidlinger, H W Sollinger
Oct 31, 2009·Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·Olivier BoillotJean-Yves Scoazec
Jan 11, 2017·The Cochrane Database of Systematic Reviews·Penny HillAngela C Webster
Dec 18, 2020·Global Health & Medicine·Tadashi Takaki, Masayuki Shimoda

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.